The FDA has updated guidance warning telehealth companies that promoting compounded drugs, including GLP-1 receptor agonists, with false or misleading claims violates federal law and prevents patients from making informed decisions about their care. The agency identified five prohibited practices…
GLP-1s
Middle-age adults who use GLP-1 medications for obesity could save an average of $192,735 in lifetime medical costs, according to a study published in June by the National Bureau of Economic Research. Researchers from Los Angeles-based University of Southern California…
Drugmakers are racing to develop next-generation obesity drugs that build on the success of products from Eli Lilly and Novo Nordisk. Among them, Pfizer, Roche, Boehringer Ingelheim and Amgen are focusing on improving convenience, reducing side effects and preserving muscle…
Eli Lilly’s oral GLP-1 therapy Foundayo (orforglipron) has outperformed oral semaglutide on blood sugar control and weight loss in a Phase 3 trial of adults with Type 2 diabetes. In the Achieve-3 study, Foundayo 17.2 milligrams delivered a 57.1% greater…
Wegovy (semaglutide) 25-milligram tablets have surpassed 3 million prescriptions in just over five months after launching Jan. 5. The milestone equates to roughly one prescription filled every five seconds and makes Wegovy one of the strongest U.S. pharmaceutical launches by…
Advertisement
As researchers continue studying GLP-1 drugs like Ozempic and Mounjaro in a range of conditions beyond their approved uses, a growing body of evidence is pointing toward a meaningful role in cancer prevention and outcomes — with some of the…
Cigna will stop covering GLP-1s for weight loss through its own employee health plan July 1, the company confirmed to Becker’s. “We regularly review our health benefits to ensure they remain sustainable, accessible and aligned with the unique needs of…
GLP-1 medications were approved for diabetes and obesity. But a rapidly expanding body of research — backed in some cases by large clinical trials and, in at least one, an FDA approval — suggests the drug class may have meaningful…
Researchers at Philadelphia-based Penn Medicine have found women who used GLP-1 medications were about 30% less likely to develop breast cancer than women who did not use the drugs. Here are five notes:
A wave of recent research is expanding what clinicians and health system leaders know about GLP-1 medications — from their place in obesity treatment to emerging benefits in oncology and gastrointestinal care. Here are six recent study findings: 1. Eli…